Institution profile

医療法人美喜有会 リペアセルクリニック

Explore the institution's name, address and registered technologies as published, along with plan classifications, score components and sources.

The ranking reflects only the registration data published by Japan's Ministry of Health, Labour and Welfare; it does not represent treatment outcomes or quality of care. Scoring method →

Source: Ministry of Health, Labour and Welfare public directory of regenerative medicine providers MHLW e-Regenerative Medicine public register · Directory archive date I: 2026-07-19 / II: 2026-09-26 / III: 2026-05-18 · Internet Archive

MHLW e-Regenerative Medicine public registerPublic document number 02E2603022 +11

Location

Prefecture
Osaka
Address
大阪市福島区福島1-1-51 堂島クロスウォーク404C

Plan classification

  • Class INot registered
  • Class IIThe medium-risk category under the law.
  • Class IIIThe low-risk category under the law.

Certified committee for regenerative medicine

  • ヴィヴィアン特定認定再生医療等委員会
  • ヴィヴィアン認定再生医療等委員会
  • 医療法人 清悠会 認定再生医療等委員会

Public score

81.9/ 100

A · Review level
25.0 / 30
B · Technologies
29.5 / 35
C · Coverage
17.9 / 25
D · Class I / II technologies
9.6 / 10

The public score is calculated from public registration information and does not reflect quality of care. Scoring method →

Position in the overall score distribution

0–100 · Public score
000–9.9 · 0 institutions
01010–19.9 · 0 institutions
2172020–29.9 · 217 institutions
3163030–39.9 · 316 institutions
7564040–49.9 · 756 institutions
2465050–59.9 · 246 institutions
1326060–69.9 · 132 institutions
417070–79.9 · 41 institutions
248080–89.9 · 24 institutions
49090–100 · 4 institutions
This institution 81.9
Public score →100

Registered technologies (12)

Stem cells (all sources) 8
Registered technologies · Japanese originalTechnology areasPlan classification
自己脂肪由来幹細胞を用いた慢性疼痛の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた変形性関節症の治療Stem cells (all sources)Adipose-derived stem cellsJoints and musculoskeletalClass II
自己脂肪由来幹細胞を用いた糖尿病の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた脳血管障害の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた脊髄損傷の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた肝障害の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた顔面萎縮症・皮膚再生治療Stem cells (all sources)Adipose-derived stem cellsSkinClass II
自己脂肪由来幹細胞と自己前骨芽細胞分化誘導上清液を用いた変形性関節症の治療Stem cells (all sources)Adipose-derived stem cellsJoints and musculoskeletalClass II
Adipose-derived stem cells 8
Registered technologies · Japanese originalTechnology areasPlan classification
自己脂肪由来幹細胞を用いた慢性疼痛の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた変形性関節症の治療Stem cells (all sources)Adipose-derived stem cellsJoints and musculoskeletalClass II
自己脂肪由来幹細胞を用いた糖尿病の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた脳血管障害の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた脊髄損傷の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた肝障害の治療Stem cells (all sources)Adipose-derived stem cellsClass II
自己脂肪由来幹細胞を用いた顔面萎縮症・皮膚再生治療Stem cells (all sources)Adipose-derived stem cellsSkinClass II
自己脂肪由来幹細胞と自己前骨芽細胞分化誘導上清液を用いた変形性関節症の治療Stem cells (all sources)Adipose-derived stem cellsJoints and musculoskeletalClass II
PRP and platelet-derived 3
Registered technologies · Japanese originalTechnology areasPlan classification
自家多血小板血漿を用いた変形性関節症の治療PRP and platelet-derivedJoints and musculoskeletalClass II
多血小板血漿を用いた皮膚再生療法PRP and platelet-derivedSkinClass III
多血小板血漿を用いた筋腱炎・靭帯炎の治療PRP and platelet-derivedJoints and musculoskeletalClass III
NK and immune cells 1
Registered technologies · Japanese originalTechnology areasPlan classification
悪性腫瘍の予防に対する自己活性化NK細胞を用いた細胞治療NK and immune cellsClass III
Joints and musculoskeletal 4
Registered technologies · Japanese originalTechnology areasPlan classification
自己脂肪由来幹細胞を用いた変形性関節症の治療Stem cells (all sources)Adipose-derived stem cellsJoints and musculoskeletalClass II
自家多血小板血漿を用いた変形性関節症の治療PRP and platelet-derivedJoints and musculoskeletalClass II
自己脂肪由来幹細胞と自己前骨芽細胞分化誘導上清液を用いた変形性関節症の治療Stem cells (all sources)Adipose-derived stem cellsJoints and musculoskeletalClass II
多血小板血漿を用いた筋腱炎・靭帯炎の治療PRP and platelet-derivedJoints and musculoskeletalClass III
Skin 2
Registered technologies · Japanese originalTechnology areasPlan classification
自己脂肪由来幹細胞を用いた顔面萎縮症・皮膚再生治療Stem cells (all sources)Adipose-derived stem cellsSkinClass II
多血小板血漿を用いた皮膚再生療法PRP and platelet-derivedSkinClass III

Certified committee for regenerative medicine

  • ヴィヴィアン特定認定再生医療等委員会
  • ヴィヴィアン認定再生医療等委員会
  • 医療法人 清悠会 認定再生医療等委員会

Public document number

  • 02E2603022
  • 02E2603023
  • 02E2603024
  • 02E2603025
  • 02E2603026
  • 02E2603027
  • 02E2603028
  • 02E2603032
  • 02E2603033
  • 03E2509010
  • 03E2509011
  • 03E2509013
Plan classification · Certified committee for regenerative medicine · Public document number
Registered technologiesPlan classificationCertified committee for regenerative medicinePublic document number
自己脂肪由来幹細胞を用いた脳血管障害の治療Class IIヴィヴィアン特定認定再生医療等委員会02E2603022
自己脂肪由来幹細胞を用いた慢性疼痛の治療Class IIヴィヴィアン特定認定再生医療等委員会02E2603023
自己脂肪由来幹細胞を用いた糖尿病の治療Class IIヴィヴィアン特定認定再生医療等委員会02E2603024
自己脂肪由来幹細胞を用いた肝障害の治療Class IIヴィヴィアン特定認定再生医療等委員会02E2603025
自己脂肪由来幹細胞を用いた変形性関節症の治療Class IIヴィヴィアン特定認定再生医療等委員会02E2603026
自己脂肪由来幹細胞を用いた顔面萎縮症・皮膚再生治療Class IIヴィヴィアン特定認定再生医療等委員会02E2603027
自家多血小板血漿を用いた変形性関節症の治療Class IIヴィヴィアン特定認定再生医療等委員会02E2603028
自己脂肪由来幹細胞と自己前骨芽細胞分化誘導上清液を用いた変形性関節症の治療Class IIヴィヴィアン特定認定再生医療等委員会02E2603032
自己脂肪由来幹細胞を用いた脊髄損傷の治療Class IIヴィヴィアン特定認定再生医療等委員会02E2603033
多血小板血漿を用いた筋腱炎・靭帯炎の治療Class IIIヴィヴィアン認定再生医療等委員会03E2509010
多血小板血漿を用いた皮膚再生療法Class IIIヴィヴィアン認定再生医療等委員会03E2509011
悪性腫瘍の予防に対する自己活性化NK細胞を用いた細胞治療Class III医療法人 清悠会 認定再生医療等委員会03E2509013

Other institutions in the same prefecture

← Institution directory
One-to-one advice

Still unsure? Ask an advisor

Use the “Chat with an advisor” button on this page (at the bottom of the screen on mobile, bottom right on desktop) to open a chat with the Stem Cell Japan advice desk. Consultation and coordination are free, and an advisor replies within one working day.

Chat with an advisor